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INTRODUCTION
Gallbladder cancer (GBC) is a relatively rare disease that has 
been traditionally considered an incurable malignancy, ow-
ing to the advanced stage at diagnosis.1,2 Currently, radical sur-
gery is the only curative option for GBC, but the extent of opera-
tion for T1/T2 GBC remains controversial. Generally, simple 
cholecystectomy alone (including laparoscopic cholecystec-
tomy) is considered adequate for the pathologic stage of T1a 
GBC, as reflected by the current National Comprehensive 
Cancer Network guidelines (version 2017). However, for GBC of 
stage T1b or greater, radical cholecystectomy is recommended, 
which includes en bloc hepatic resection (segments IVB and V) 
and lymphadenectomy to clear all lymph nodes in the porta 
hepatis with/without bile duct resection. Nevertheless, the 
surgical extent for T1b and T2 GBC has been highly debated, 
and evidence of increased survival after radical cholecystecto-
my in patients with T1b GBC is lacking.3 Moreover, guidelines 
for surgical extent also vary greatly among institutions, and the 
global prevalence of GBC is imbalanced with high incidence 
rates reported in South America and Asia.4 However, the high-
er recurrence rate reported with simple cholecystectomy in cas-
es with stage T1b suggests that more radical operations should 
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be considered.5
With regard to the extent of radical cholecystectomy, the pol-
icy for T1/T2 GBC at Severance Hospital traditionally includ-
ed liver resection. However, our earlier experiences showed 
that recurrences in the liver rarely occur, and we opted not to 
resect the liver during radical cholecystectomy.6 We encoun-
tered recurrences in distant lymph nodes, especially para-aortic 
lymph nodes after radical cholecystectomy; therefore, begin-
ning in 2005, we routinely extended lymphadenectomies to 
include the para-aortic lymph nodes in patients with T1/T2 
GBC. Moreover, our experiences with complications in the 
common bile duct after radical cholecystectomy have led us to 
include the insertion of a T-tube as the final step of operation. 
The present study analyzes the oncologic outcomes of patients 
at Severance Hospital undergoing these treatments with ex-
tended lymphadenectomy and without liver resection.
MATERIALS AND METHODS
Patients and study design
From January 2005 to December 2017, 164 patients with GBC 
underwent operation by a single surgeon (WJL) at Severance 
Hospital. We retrospectively reviewed the cases of 113 patients 
who underwent extended cholecystectomy without hepatecto-
my and were pathologically determined to be at stages T1 and 
T2. Pathological results, including T and N stages, were defined 
according to the American Joint Committee on Cancer (AJCC) 
cancer staging manual, 7th edition. Patients who underwent ad-
ditional hepatectomy under the suspicion of T3 tumor were ex-
cluded as they were not within our treatment algorithm. Four 
patients who underwent palliative operations without radical 
cholecystectomy were also excluded. This study was reviewed 
and approved by the Institutional Review Board of Yonsei Uni-
versity College of Medicine, Seoul, Republic of Korea (IRB: 
4-2017-0262).
Preoperative evaluation
Patients with suspected GBC from abdominal ultrasonography 
and/or computed tomography underwent positron emission 
tomography to assess distant metastases. Endoscopic ultraso-
nography was used to assess tumor invasion depth. In cases 
with incidentally diagnosed GBC, positron emission tomogra-
phy was performed after laparoscopic cholecystectomy to eval-
uate possible metastatic lesions. Carbohydrate antigen 19-9 
was evaluated as the tumor marker. 
Operative strategy and adjuvant treatment
A schematic detailing the treatment algorithm is shown in Fig. 1. 
Three different approaches to radical cholecystectomy were 
employed: open or minimally invasive (laparoscopic and ro-
botic). If preoperative evaluation suggested a T2 lesion with 
suspicious lymph node metastasis, the operation was per-
formed using an open approach. For T1 and T2 lesions with-
out suspicious lymph node metastasis, laparoscopic cholecys-
tectomy was performed initially. During cholecystectomy, the 
cystic plate was completely removed with the gallbladder to 
avoid exposing the subserosal layer. If the results of a full-thick-
ness frozen biopsy were positive for malignancy, radical lymph 
node dissection was performed. The extents of lymphadenec-
tomy were hepatoduodenal (#12), common hepatic artery (#8), 
retropancreatic (#13), and para-aortic (#16). T-tubes were rou-
tinely inserted into the common bile duct. As noted above, liver 
resection was not performed for all T1 and T2 lesions. If the fro-
zen biopsy results were negative or indeterminate, no further 
operation was performed until the pathology was confirmed. If 
the results confirmed a T1b or T2 lesion, radical lymph node 
dissection was subsequently performed. Cases with T1b and T2 
lesions referred from other hospitals after laparoscopic chole-
cystectomy underwent reoperation via an open approach.
The role of adjuvant chemotherapy remains unclear, with 
some reports of benefit in node-positive GBC or R1 disease.7,8 
Therefore, adjuvant chemotherapy was only considered in cas-
es of lymph node metastasis or gallbladder perforation during 
operation. Postoperative complications were graded according 
to Clavien–Dindo classifications.9 
Statistical analysis 
All statistical analyses were performed using Statistical Pack-
age for Social Sciences version 20 (IBM Corp., Armonk, NY, 
USA). For each quantitative variable, Shapiro–Wilk test was 
used as a test of normality. Disease-specific survival and dis-
ease-free survival were analyzed using Kaplan–Meier method 
and compared by log-rank tests. Cox proportional hazards 
model was used for multivariate survival analysis. Statistical 
significance was set as p value <0.05.
Permanent 
pathology
Full-thickness frozen biopsy
Preoperative evaluation:
US/CT, PET, EUS
T1/T2 lesion: 
Tumor limited to gallbladder
Operation: 
Laparoscopic cholecystectomy
Positive LN: 
Adjuvant chemotherapy
T1b or T2: 
Radical LN dissection
T1a or benign: 
No more surgery
Positive: 
Radical LN dissection 
(Open/Robotic/Laparoscopic)
Negative or deferred: 
No more surgery
Fig. 1. Treatment algorithm for gallbladder carcinoma. US, ultrasonogra-
phy; CT, computed tomography; PET: positron emission tomography; 
EUS, endoscopic ultrasonography; LN, lymph node.
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RESULTS
Clinicopathologic characteristics
For the 109 patients included in our analysis, the mean age 
was 65±9 years, and 47 patients (43%) were male. Forty-five 
patients (41%) were diagnosed with incidental GBC. Among 
them, 11 patients (24%) were diagnosed with T1a GBC and 
did not undergo further operations. The mean level of carbo-
hydrate antigen 19-9 was 13.0±16.8 U/mL. The median follow-
up was 50 months (range, 5–145 months). The mean number 
of retrieved lymph nodes was 14±9 lymph nodes. Node-posi-
tive GBC was found in 14 patients (13%). Among them, 12 pa-
tients underwent adjuvant chemotherapy and two patients re-
fused adjuvant therapy.
Comparison of clinicopathologic outcomes between 
T stages
Clinicopathologic characteristics according to T stage are 
shown in Table 1. Clinical characteristics did not differ among 
T stages. There were no differences in terms of the locations of 
tumors, i.e., hepatic vs. peritoneal sides (p=0.805); however, 
tumors involving hepatic side were more frequent (n=63, 58%). 
With regard to histologic differentiation, higher T stages were 
significantly associated with poorly differentiated GBC (p= 
0.004). Two patients in T2 group with poorly differentiated 
GBC showed combined neuroendocrine features in the patho-
logic report. Significantly higher lymph node metastasis was 
noted in T2 group than those in T1b and T1a groups (21% vs. 
4% and 0%, respectively, p<0.001). The numbers of retrieved 
lymph nodes were higher for T1b and T2 groups than for T1a 
group (p<0.001) (Table 1). In T1a group, six patients who were 
diagnosed with incidental GBC did not undergo lymph node 
dissection, whereas 15 patients did as a higher T stage was sus-
pected.
There were no significant differences between stages in terms 
of complications (p=0.467). All grade I complications were ei-
Table 1. Clinicopathologic Characteristics according to T Stage
Variables T1a (n=21) T1b (n=26) T2 (n=62) p value
Age (yr) 62 (40–81) 67 (35–82) 65 (47–81) 0.331
Male 9 (43) 10 (38) 28 (45) 0.836
CA 19-9 (U/mL) 10.1 (1.2–83.6) 6.7 (0.6–51.7) 8.4 (0.1–96.8) 0.380
Incidental gallbladder cancer 11 (52) 12 (46) 22 (35) 0.359
Tumor size (cm) 2.0 (0.1–4.5) 2.0 (0.1–4.2) 2.2 (0.3–8.5) 0.160
Tumor location 0.805
Hepatic side 11 (52) 16 (62) 36 (58)
Peritoneal side 10 (48) 10 (38) 26 (42)
Histologic differentiation 0.004
Well 19 (90) 21 (81) 31 (50)
Moderate 2 (10) 4 (15) 23 (37)
Poor 0� 1 (4) 8 (13)
N stage <0.001
Nx 6 (29) 0� 0�
N0 15 (71) 25 (96) 49 (79)
N1 0� 1 (4) 11 (18)
N2 0� 0� 2 (3) 0.273
Lymphovascular invasion 0� 2 (8) 9 (15) 0.881
Perineural invasion 1 (5) 1 (4) 3 (5) <0.001
Median number of retrieved LNs 2 (0–19) 16 (2–28) 18 (3–35)
Operation method <0.001
Laparoscopic 16 (76) 5 (19) 10 (16)
Robotic 3 (14) 4 (15) 5 (8)
Open 2 (10) 17 (65) 47 (76)
Complications (Clavien-Dindo) 0.467
I 0� 1 (4) 7 (11)
II 1 (5) 0� 4 (6)
III 1 (5) 2 (8) 3 (5)
Adjuvant therapy 0� 1 (4) 11 (18) 0.028
LN, lymph node.
Values are presented as median (range) or n (%) unless otherwise indicated.
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ther fever or wound seroma. Grade II complications were chy-
lous leakage (two cases), which were medically managed, and 
abscess formation (three cases), which were managed with 
antibiotics. Grade III complications were postoperative bile 
leakage requiring endoscopic retrograde biliary drainage (five 
cases), and intra-abdominal abscess formation requiring per-
cutaneous catheter drainage (one case).
Operative technique and postoperative complications
Open radical cholecystectomies were performed in 66 patients 
(61%), whereas the approaches were laparoscopic for 31 pa-
tients (28%) and robotic for 12 patients (11%). The median 
(range) operation times for open, laparoscope, and robotic rad-
ical cholecystectomies were 183 (95–340), 73 (30–173), and 231 
(172–278) min, respectively (p<0.001). There were three cases 
of open conversion during minimally invasive approaches: 
one from phrenic artery injury (laparoscopic approach) and 
two from renal vein injury and aortic wall bleeding (robotic ap-
proach).
There were no significant differences in complications be-
tween operative techniques (p=0.066). For minimally invasive 
approaches, there were no complications in laparoscopic group, 
but three complications (24%) were observed in robotic group: 
grade I for fever, which was treated conservatively; grade II for 
intra-abdominal abscess formation requiring antibiotics; and 
grade IIIA requiring endoscopic retrograde biliary drainage 
due to postoperative bile leakage. There were 13 complications 
(21%) in patients undergoing an open approach: six cases were 
grade I for fever and wound seroma, four in grade II (including 
two cases of postoperative chylous leakage and two cases of 
intra-abdominal abscess formation requiring pharmacologic 
treatments), and three in grade IIIA (including two cases of 
endoscopic retrograde biliary drainage due to postoperative 
bile leakage and one case of percutaneous catheter drainage for 
intra-abdominal abscess formation).
Oncologic outcomes
There were four GBC-related mortalities during the study pe-
riod, and the 5-year disease-specific survival rate was 97%. 
There were no significant differences according to T stage in 
disease-specific survival (p=0.366; Fig. 2A) or disease-free sur-
vival (p=0.457; Fig. 2B). In all T stages, the median survival was 
not reached for analysis. In N2 disease, significantly poor on-
cologic outcomes (5-year disease-specific survival: 50%, 5-year 
disease-free survival: 0%; Fig. 3) were observed. Oncologic out-
comes were not associated with the tumor location (Fig. 4) nor 
the type of surgical approach (Fig. 5).
Recurrence pattern
The details on recurrence for each GBC stage are shown in Ta-
ble 2. Overall, there were six cases of recurrence, with a 5-year 
disease-free survival rate of 92.4%. In cases with T1a GBC, no 
lymph node metastasis was found in 15 patients who under-
went lymph node dissection. Among the 26 patients with T1b 
lesions, there was only one patient (4%) with lymph node me-
tastasis, and two patients (8%) had recurrence. For T2 GBC, 13 
patients (22%) had lymph node metastasis, two of whom were 
staged N2: one patient had only single lymph node metastasis 
in retropancreatic lymph nodes from total of 26 lymph nodes 
investigated, and the other patient had one metastatic para-
aortic lymph node and four metastatic hepatoduodenal lymph 
nodes from a total of 20 lymph nodes investigated. These pa-
tients with N2 staging showed recurrences. Two patients show-
ing poorly differentiated adenocarcinoma with neuroendo-
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Fig. 2. Oncologic outcomes according to T stage. (A) Disease-specific survival (DSS). (B) Disease-free survival (DFS).
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crine features had recurrence within 1 year after the operation.
DISCUSSION
Historically, GBC has been associated with pessimistic onco-
logic outcomes. In 1924, Blalock10 wrote that “in malignancy 
of the gallbladder, when a diagnosis can be made without ex-
ploration, no operation should be performed, in as much as it 
only shortens the patient’s life.” With improvements in radiol-
ogy and the invention of laparoscopic operations, early diag-
noses of GBC have become more frequent. However, the cu-
rative options are limited to radical operations, as GBC has a 
propensity for early dissemination and is proximal to the liver 
and major vasculature. Recently, favorable outcomes after less 
radical cholecystectomies have been reported in patients with 
T1/T2 GBC, with some reports on the safety and non-inferior 
oncologic outcomes of laparoscopic approach.11-14 However, 
there is no consensus on the extent of surgery during radical 
cholecystectomy except for T1a GBC, in which laparoscopic 
simple cholecystectomy is adequate. Further lymph node dis-
section may still be indicated, as frozen biopsies during opera-
tions cannot always discriminate between T1 and T2 GBC.
Clarification of the oncologic outcomes for GBC is difficult 
due to the heterogeneity of operative techniques. For example, 
the extent of surgery differs among surgeons and institutions. 
Therefore, to compare oncologic outcomes based on the extent 
of surgery, we analyzed cases involving a single surgeon (WJL) 
at Severance Hospital, where laparoscopic operations for GBC 
have been performed since 1993. At that time, if a patient was 
diagnosed with incidental T1a GBC, routine follow-up was 
scheduled. For those with T1b GBC or higher, open radical cho-
lecystectomies were performed, unless the patients refused for 
personal reasons. Our previous reports on patients who did not 
undergo further radical cholecystectomy due to personal rea-
sons or the patients’ general condition showed that the 5-year 
survival rates of GBC patients with T1a, T1b, and T2 lesions 
were 100%, 75%, and 56.2%, respectively.15 Two cases of recur-
rences in para-aortic lymph nodes were noted after radical 
cholecystectomy, including only regional lymphadenectomy, 
in patients with T2 GBC at 1 month and 5 months. There was 
no recurrence in the liver bed, which extends from the cystic 
plate, in any of the patients. Starting in 2005, with the introduc-
tion of robotic system at Severance Hospital, minimally invasive 
radical cholecystectomies, including the robotic approach, were 
also performed. Our results have shown no differences in onco-
logic outcomes among different surgical approaches. Therefore, 
for T1/T2 GBC, having a consistent and reasonable operative 
principle is more important than the mode of surgical approach.
Our anecdotal experiences have indicated that the dissection 
of regional lymph nodes along with para-aortic lymph nodes 
may reduce recurrence. Para-aortic lymph nodes are the final 
destination in the abdominal lymphatic route from the gallblad-
der via the cholecysto-retropancreatic pathway and the retro-
portal node.16 However, evidence on the role of extensive lymph-
adenectomy is lacking. Tsukada, et al.17 reported that in T2 GBC, 
metastases in para-aortic lymph nodes were discovered in 12% 
of cases, whereas Ogura, et al.18 reported lymph node metastases 
in 44.3%, with 2.5% of T1a and 15.6% of T1b cases also showing 
metastases. Nevertheless, para-aortic lymphadenectomy did not 
seem to provide any survival benefit.19 In contrast, our findings 
suggest a benefit of extensive lymphadenectomy on the onco-
logic outcomes of GBC patients without pre-existing lymph 
node metastases. 
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Fig. 3. Oncologic outcomes according to N stage. (A) Disease-specific survival (DSS). (B) Disease-free survival (DFS).
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One recent meta-analysis of T1 GBC found comparable sur-
vival outcomes between simple and extended cholecystecto-
mies,20 whereas another meta-analysis reported conflicting 
results and suggested an improved prognosis associated with 
liver resection and lymph node resection for stage T1b GBC or 
higher.21 However, the authors of both meta-analyses noted that 
a lack of essential data for comparison and a lack of standard-
ization in operative extent and definition can limit the inter-
pretation of the results. Additionally, since liver parenchyme is 
not involved in T1/T2 GBC, the complete excision of the cystic 
plate along with the gallbladder may be sufficient. Indeed, our 
experiences after the implementation of these principles in 
2005 have indicated better oncologic outcomes for GBC, espe-
cially for T2 tumors. The 5-year disease-specific survival rate 
was 97.1% at Severance Hospital, compared to rates ranging 
from 69.4% to 90.2% in previous studies.6,14,22 Although this 
study found one recurrence in the liver, it was bi-lobular and 
distant from the cystic plate. Horiguchi, et al.23 also reported no 
difference in disease-free survival rates between patients re-
ceiving cystic bed resection only and those also undergoing liver 
resection. Therefore, the complete excision of the cystic plate 
should be adequate for T1/T2 GBC.
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Fig. 4. Oncologic outcomes according to tumor location. (A) Disease-specific survival (DSS). (B) Disease-free survival (DFS). (C) DSS for T2. (D) DFS for T2.
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Nortably, the percentage of incidental GBC cases following 
cholecystectomy in the present report was higher than those 
reported for laparoscopic cholecystectomies, which ranged 
from 0.2% to 1.1%.24 This may be due to the fact that Severance 
Hospital is a tertiary referral hospital. Additionally, our results 
indicate that the location of the tumor, whether on the hepatic 
or peritoneal side, does not influence the oncologic outcome, 
even though the current 8th AJCC staging system further di-
vides T2 stage accordingly. 
In terms of recurrence, six incidences were observed in our 
study group. Two cases of recurrence showed that GBC was 
poorly differentiated with neuroendocrine features, which is 
known to behave more aggressively.25 Among the remaining 
four cases, one patient was initially diagnosed with T1b lesion 
without lymph node metastasis, and had recurrence at the para-
aortic lymph node 14 months later. This may have resulted from 
an incomplete para-aortic lymph node dissection; therefore, 
radical cholecystectomy in T1b should be sought more actively.
Regarding postoperative complications, some patients showed 
postoperative bile leakage. These complications may have re-
sulted from complete and radical dissections of hepatoduo-
denal lymph nodes, which completely expose the common 
bile duct and disrupt its blood supply. We now routinely insert 
T-tubes to prevent such postoperative biliary complications. 
The limitations of the present study include the limited num-
ber of patients analyzed, as well as the inherent selection bias 
resulting from the retrospective design and selection criteria 
of the study. Five patients who underwent additional hepa-
tectomy under the suspicion of T3 tumor were excluded from 
this study. The operative finding showed that the possibility of 
acute inflammation and liver invasion could not be completely 
excluded. Therefore, the current treatment algorithm should be 
applied with discretion in patients with acute inflammation. 
Furthermore, these results were based on the experience of a 
Table 2. Lymph Node Status and Recurrence Patterns according to T Stage
 T stage (n=112) Nodal status Number of recurrence Site of recurrence Time of recurrence Survival months Status
 T1a (n=21) Nx* (n=6, 29%) None -
N0 (n=15, 71%) None -
 T1b (n=26) N0 (n=25, 96%) 1 (4%) Para-aortic LN 14 25 Dead
N1 (n=1, 4%) 1 (100%) Spine 53 60 Dead
  T2 (n=62) N0 (n=49, 79%) 1 (2%) Liver‡   6 20 Alive
N1 (n=11, 18%) 1 (9%) Regional LN, Supraclavidular LN 13 15 Alive
N2† (n=2, 3%) 2 (100%) Common bile duct 52 65 Dead
Paraortic LN‡   8 36 Dead
LN, lymph node.
*Nx represents without lymph node dissection for examination; †N2 represents positive para-aortic lymph nodes; ‡Histologic grade showed poorly differentiated 
adenocarcinoma with neuroendocrine features.
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Fig. 5. Oncologic outcomes according to surgical approach. (A) Disease-specific survival (DSS). (B) Disease-free survival (DFS). 
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single surgeon (WJL). Nevertheless, the preventive role of ex-
tensive lymphadenectomy, including para-aortic lymph node 
dissection, should be given further attention, and more sur-
geons should consider our operative principle to enable a large-
scale cohort study.
A complete R0 resection in GBC is the standard of care in 
patients with localized disease. However, there is no consen-
sus on the extent of radical cholecystectomy for T1/T2 GBC, 
partly due to the low incidence of GBC that impedes random-
ized controlled trials to establish optimal treatment modalities. 
Here, we report on our experiences with an operative principle 
at Severance Hospital, which indicates that extended lymph-
adenectomy with para-aortic lymph node dissection without 
liver resection for T1/T2 GBC produces favorable oncologic 
outcomes.
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